Pharmaceutical

XKDCT-080 by Guangdong Xiankangda Biotechnology for Colorectal Cancer: Likelihood of Approval

XKDCT-080is under clinical development by Guangdong Xiankangda Biotechnology and currently in Phase II for Colorectal Cancer.

Jul 1, 2023 - 20:00
XKDCT-080is under clinical development by Guangdong Xiankangda Biotechnology and currently in Phase II for Colorectal Cancer.
Read the original article

Tags:

Previous Article

Cold agglutinin disease by NovelMed Therapeutics for Acquired (Autoimmune) Hemol...

Next Article

ABBV-444 by AbbVie for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA’s Woodcock reflects on more than 30 years at agency — and hints at what’s next

STAT+: FDA’s Woodcock reflects on more than 30 years at...

Jan 30, 2024

UCB to divest China neurology and allergy business for $680m

UCB to divest China neurology and allergy business for ...

Aug 27, 2024

Johnson & Johnson sees highest patent filings and grants during August in Q3 2023

Johnson & Johnson sees highest patent filings and grant...

Nov 24, 2023